Aytu BioPharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Revenue	62.64	66.38	65.18	73.8	96.67	65.63
Revenue Growth (YoY)	2.00%	1.84%	-11.68%	-23.66%	47.29%	137.52%
Cost of Revenue	20.77	20.55	16.13	21.57	46.39	36.43
Gross Profit	41.87	45.83	49.05	52.23	50.28	29.2
Selling, General & Admin	39.09	38.29	42.04	49.77	69.88	55.81
Research & Development	0.38	1.33	2.77	3.98	12.66	5.62
Amortization of Goodwill & Intangibles	2.81	3.68	3.68	3.69	5.84	6.01
Operating Expenses	42.28	43.29	48.49	57.44	88.39	67.44
Operating Income	-0.41	2.54	0.57	-5.21	-38.1	-38.24
Interest Expense	-2.71	-3.7	-5.06	-5.15	-0.01	-0.01
Other Non Operating Income (Expenses)	-12.86	-2.22	-3.13	5.22	0.86	-2.04
EBT Excluding Unusual Items	-15.98	-3.38	-7.63	-5.14	-37.26	-40.29
Merger & Restructuring Charges	-	-2.1	-2.16	-	-	-7.81
Impairment of Goodwill	-	-	-	-	-65.8	-
Asset Writedown	-8.26	-8.26	-	-2.73	-7.66	-12.83
Other Unusual Items	-	-	-0.59	0.58	1.82	2.89
Pretax Income	-24.24	-13.75	-10.38	-7.29	-108.89	-58.03
Income Tax Expense	0.32	0.44	2.14	0.26	-0.11	0.26
Earnings From Continuing Operations	-24.56	-14.18	-12.52	-7.55	-108.78	-58.29
Earnings From Discontinued Operations	0.12	0.62	-3.32	-9.5	-	-
Net Income	-24.44	-13.56	-15.84	-17.05	-108.78	-58.29
Net Income to Common	-24.44	-13.56	-15.84	-17.05	-108.78	-58.29
Shares Outstanding (Basic)	8	6	6	3	1	1
Shares Outstanding (Diluted)	8	6	6	3	1	1
Shares Change (YoY)	38.73%	13.40%	65.81%	127.22%	75.54%	270.57%
EPS (Basic)	-3.02	-2.16	-2.86	-5.11	-74.01	-69.61
EPS (Diluted)	-3.02	-2.16	-2.86	-5.11	-74.01	-69.61
Free Cash Flow	-0.7	-2.17	-1.72	-5.13	-28.82	-28.31
Free Cash Flow Per Share	-0.09	-0.34	-0.31	-1.54	-19.61	-33.80
Gross Margin	66.84%	69.04%	75.26%	70.77%	52.02%	44.49%
Operating Margin	-0.66%	3.82%	0.87%	-7.05%	-39.42%	-58.26%
Profit Margin	-39.02%	-20.43%	-24.31%	-23.11%	-112.53%	-88.81%
Free Cash Flow Margin	-1.11%	-3.26%	-2.63%	-6.95%	-29.82%	-43.13%
EBITDA	4.03	7.91	7.29	2.49	-27.96	-29.04
EBITDA Margin	6.43%	11.92%	11.18%	3.38%	-28.92%	-44.25%
D&A For EBITDA	4.44	5.38	6.73	7.7	10.15	9.2
EBIT	-0.41	2.54	0.57	-5.21	-38.1	-38.24
EBIT Margin	-0.66%	3.82%	0.87%	-7.05%	-39.42%	-58.26%
Advertising Expenses	-	-	-	-	13.6	15.2

Updated Feb 3, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q